Dr. Postow Discusses New Targets in Melanoma

Source: OncLive, April 2018

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses new targets in melanoma.
In the treatment of patients with melanoma, well known targets such as CTLA4 and PD-1 have been at the forefront of research. Ipilimumab (Yervoy) has been shown to successfully target CTLA-4, while pembrolizumab (Keytruda) and nivolumab (Opdivo) target PD-1. But, Postow says that new immunotherapy targets are emerging in 2018.
IDO and LAG-3 both have very interesting emerging data in melanoma, says Postow. There are also completely new targets that act through various mechanisms, such as inhibiting metabolism in the tumor microenvironment, he adds.